Leerink Partnrs downgraded shares of 10x Genomics (NASDAQ:TXG – Free Report) from a strong-buy rating to a hold rating in a ...

Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management ...

Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by equities researchers at Stifel Nicolaus from ...

Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by Morgan Stanley from $28.00 to $26.00 in a research ...

Genomics (NASDAQ:TXG – Get Free Report) is projected to announce its earnings results after the market closes on Thursday, February 20th. Analysts expect 10x Genomics to post earnings of ($0.29) per ...

Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 ...

Analysts at Leerink Partnrs decreased their Q1 2025 earnings estimates for shares of 10x Genomics in a research note issued to investors on Thursday, February 13th. Leerink Partnrs analyst P. Souda ...

Leerink Partners cut shares of 10x Genomics (NASDAQ:TXG – Free Report) from an outperform rating to a market perform rating ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million.

Genomics (NASDAQ:TXG – Free Report) had its price objective decreased by UBS Group from $20.00 to $14.00 in a research report ...

On Wednesday, 10x Genomics Inc (NASDAQ:TXG) reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of ...

Genomics (NASDAQ:TXG – Free Report) had its price objective lowered by Canaccord Genuity Group from $20.00 to $18.00 in a ...